Zacks David N, Kocab Andrew J, Choi Joanne J, Gregory-Ksander Meredith S, Cano Marisol, Handa James T
Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA.
ONL Therapeutics, Inc., Ann Arbor, MI 48104, USA.
J Clin Med. 2022 Jan 25;11(3):592. doi: 10.3390/jcm11030592.
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the developed world. While great advances have been made in the treatment of the neovascular ("wet") form of the disease, there is still a significant need for therapies that prevent the vision loss associated with the advanced forms of dry, atrophic AMD. In this atrophic form, retinal pigment epithelial (RPE) and photoreceptor cell death is the ultimate cause of vision loss. In this review, we summarize the cell death pathways and their relation to RPE and retinal cell death in AMD. We review the data that support targeting programmed cell death through inhibition of the Fas receptor as a novel approach to preserve these structures and that this effect results from inhibiting both canonical death pathway activation and reducing the associated inflammatory response. These data lay the groundwork for current clinical strategies targeting the Fas pathway in this devastating disease.
年龄相关性黄斑变性(AMD)是发达国家不可逆失明的主要原因。虽然在治疗该疾病的新生血管(“湿性”)形式方面已取得巨大进展,但对于预防与晚期干性萎缩性AMD相关的视力丧失的疗法仍有巨大需求。在这种萎缩形式中,视网膜色素上皮(RPE)和光感受器细胞死亡是视力丧失的最终原因。在本综述中,我们总结了细胞死亡途径及其与AMD中RPE和视网膜细胞死亡的关系。我们回顾了支持通过抑制Fas受体靶向程序性细胞死亡作为一种保留这些结构的新方法的数据,并且这种作用是通过抑制经典死亡途径激活和减少相关炎症反应而产生的。这些数据为目前针对这种毁灭性疾病中Fas途径的临床策略奠定了基础。